Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoSTEP: Short-term Sintilimab + Chemo in TNBC
NCT05843292Phase 4Not yet recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in triple-negative breast cancer (TNBC), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Pathologic Complete Response Rates. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05843292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05843292.